Alx Oncology Holdings
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $255.94 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Alx Oncology Holdings had its IPO on 2020-07-17 under the ticker symbol ALXO.
The company operates in the Healthcare sector and Biotechnology industry. Alx Oncology Holdings has a staff strength of 55 employees.
Shares of Alx Oncology Holdings opened at $4.73 at the start of the last trading session i.e. 2023-03-21.
The stocks traded within a range of $4.7 - $5.07, and closed at $4.81.
This is a +4.34% increase from the previous day's closing price.
A total volume of 1,071,572 shares were traded at the close of the day’s session.
In the last one week, shares of Alx Oncology Holdings have slipped by -14.56%.
Alx Oncology Holdings 's Key Ratios
Alx Oncology Holdings has a market cap of $255.94 million, indicating a price to book ratio of 1.5268 and a price to sales ratio of 5906.2383.
In the last 12-months Alx Oncology Holdings ’s revenue was $0 with a gross profit of $107000 and an EBITDA of $-123418000. The EBITDA ratio measures Alx Oncology Holdings 's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alx Oncology Holdings ’s operating margin was 0% while its return on assets stood at -21.55% with a return of equity of -36.07%.
In Q3, Alx Oncology Holdings ’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Alx Oncology Holdings ’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alx Oncology Holdings ’s profitability.
Alx Oncology Holdings stock is trading at a EV to sales ratio of 4254.356 and a EV to EBITDA ratio of -1.2958. Its price to sales ratio in the trailing 12-months stood at 5906.2383.
Alx Oncology Holdings stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $317.69 million
- Total Liabilities
- $25.24 million
- Operating Cash Flow
- $13.70 million
- Capital Expenditure
- $1.04 million
- Dividend Payout Ratio
Alx Oncology Holdings ended 2023 with $317.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $317.69 million while shareholder equity stood at $286.96 million.
Alx Oncology Holdings ended 2023 with $0 in deferred long-term liabilities, $25.24 million in other current liabilities, 41000.00 in common stock, $-294758000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $49.05 million and cash and short-term investments were $284.91 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Alx Oncology Holdings ’s total current assets stands at $290.81 million while long-term investments were $8.22 million and short-term investments were $235.86 million. Its net receivables were $700000.00 compared to accounts payable of $5.88 million and inventory worth $0.
In 2023, Alx Oncology Holdings 's operating cash flow was $13.70 million while its capital expenditure stood at $1.04 million.
Comparatively, Alx Oncology Holdings paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Alx Oncology Holdings stock is currently trading at $4.81 per share. It touched a 52-week high of $20.4 and a 52-week low of $20.4. Analysts tracking the stock have a 12-month average target price of $33.43.
Its 50-day moving average was $7.84 and 200-day moving average was $10.13 The short ratio stood at 25.87 indicating a short percent outstanding of 0%.
Around 257% of the company’s stock are held by insiders while 10165.7% are held by institutions.
Frequently Asked Questions About Alx Oncology Holdings
Similar Industry Stocks (Biotechnology)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin’s lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company’s pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.